Related Experiment Video
Updated: Sep 25, 2025

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
Antihypertensive Drug Combinations Modify Cisplatin-induced Acute Kidney Injury
Koji Takeuchi1, Rintaro Sogawa1, Satoko Tsuruhashi1
1Department of Pharmacy, Saga University Hospital, Saga, Japan.
Background/Aim:
There is limited evidence about the nephrotoxicity of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors with concomitant cisplatin (CDDP). We investigated whether combinations of antihypertensive drugs are associated with CDDP-related acute kidney injury (AKI) using the Japanese Adverse Drug Event Report database.
Patients And Methods:
We analysed 544,864 reports in the database from 2004 to 2020. A reporting odds ratio (ROR) and confidence interval (CI) with adjustment for potential confounding factors was calculated for AKI for each drug and the combined use of the drugs and CDDP.
Results:
CDDP, CCBs, and RAS inhibitors were all detected signals for AKI. The ROR in cases with concomitant use of CCBs, RAS inhibitors, and CDDP (adjusted ROR 7.28; 95% CI=5.56-9.54) was higher than that in cases with use of each drug.
Conclusion:
AKI may require more attention when patients receiving CDDP take CCBs and RAS inhibitors together.
Insights
Concomitant use of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors with cisplatin (CDDP) significantly increases the risk of acute kidney injury (AKI). Healthcare providers should monitor patients closely for AKI when these drug combinations are prescribed.
Area of Science:
- Nephrology
- Pharmacology
- Oncology
Background:
- Limited evidence exists on the nephrotoxicity of combined calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors with cisplatin (CDDP).
- Acute kidney injury (AKI) is a potential adverse effect of CDDP treatment.
Purpose of the Study:
- To investigate the association between antihypertensive drug combinations and CDDP-related AKI.
- To evaluate the risk of AKI when CCBs and RAS inhibitors are used concurrently with CDDP.
Main Methods:
- Analysis of 544,864 reports from the Japanese Adverse Drug Event Report database (2004-2020).
- Calculation of reporting odds ratios (ROR) and confidence intervals (CI) for AKI, adjusting for confounding factors.
- Assessment of individual drug use and combined use with CDDP.
Main Results:
- CDDP, CCBs, and RAS inhibitors were all identified as risk factors for AKI.
- Concomitant use of CCBs, RAS inhibitors, and CDDP showed a significantly higher ROR for AKI (adjusted ROR 7.28; 95% CI=5.56-9.54) compared to individual drug use.
- The combined drug regimen presented a notable signal for AKI.
Conclusions:
- Concomitant use of CCBs and RAS inhibitors with CDDP is associated with an increased risk of AKI.
- Increased vigilance for AKI is warranted in patients receiving CDDP who are also taking CCBs and RAS inhibitors.
- This finding highlights the importance of careful medication management in cancer patients undergoing chemotherapy.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics

